Don't Rule Out Sulfonylureas for Type 2 Diabetes

All the hype and TV ads about new drugs for type 2 diabetes will raise questions about the role of sulfonylureas.

The spotlight has been on Jardiance (empagliflozin), Invokana (canagliflozin), and Victoza (liraglutide)...since there's evidence they reduce CV risk in diabetes patients with CV disease or at high CV risk.

Plus they have a low hypoglycemia risk and may lead to weight loss.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote